← Back to Clinical Trials
Recruiting NCT07188064

NCT07188064 A Study Looking at a New Nerve Surgery to Help Men Regain Erections After Prostate Cancer Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07188064
Status Recruiting
Phase
Sponsor Sir Mortimer B. Davis - Jewish General Hospital
Condition Prostate Cancer
Study Type INTERVENTIONAL
Enrollment 100 participants
Start Date 2026-01-30
Primary Completion 2028-11

Eligibility & Interventions

Sex Male only
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Post radical prostatectomy nerve restoration procedure (PRP-NR)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 100 participants in total. It began in 2026-01-30 with a primary completion date of 2028-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A single arm prospective pilot trial evaluating the 1-year erectile recovery outcomes and the safety of patients undergoing a somatic to autonomic nerve grafting procedure for restoration of erectile function in patients who have lost erectile function following radical prostatectomy for prostate cancer. During this study a total of 100 patients who have persistent erectile dysfunction for more than 18 months post prostatectomy will undergo a post radical prostatectomy nerve restoration procedure (PRP-NR).

Eligibility Criteria

Inclusion Criteria: * Patients with persistent post prostatectomy erectile dysfunction as defined below: 1. Severe ED (IIEF score 5-7) and more than 12 months from prostatectomy OR 2. Moderate ED (IIEF score 8-11) and more than 18 months from prostatectomy * Patients must have had good pre-prostatectomy erectile function with a baseline IIEF score of ≥17 on self-reported assessment of historic function. Exclusion Criteria: * Patients aged \< 18 years at diagnosis * Legally incapable patients * Patients \>5 years from prostatectomy. * Bilateral open inguinal hernia repair * Patients with pre-existing significant neurologic disease * Diabetes with evidence of peripheral nerve involvement and end organ dysfunction * Coronary artery disease with unstable angina * Mood disorder (anxiety/depression) with change in medical therapy within last 3 months * Pre-existing penile base surgery which would prevent grafting technique including suprapubic liposuction, suspensory ligament release * Pre-existing penile prosthesis * Current use of androgen deprivation therapy * Use of medications for chronic nerve pain (gabapentin, amitriptyline, nortriptyline, pregablin) * Previous untreated penile trauma * Patients deemed medically unfit for surgery

Contact & Investigator

Central Contact

Victor McPherson, MD

✉ victor.mcpherson@mcgill.ca

📞 514-340-8222

Frequently Asked Questions

Who can join the NCT07188064 clinical trial?

This trial is open to male participants only, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07188064 currently recruiting?

Yes, NCT07188064 is actively recruiting participants. Contact the research team at victor.mcpherson@mcgill.ca for enrollment information.

Where is the NCT07188064 trial being conducted?

This trial is being conducted at Montreal, Canada.

Who is sponsoring the NCT07188064 clinical trial?

NCT07188064 is sponsored by Sir Mortimer B. Davis - Jewish General Hospital. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology